Allogeneic Transplantation
Lymphoma Trials (B- and T-cell)
COMIRB: 24-0458
A Phase 1a/1b Trial in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a fenretinide phospholipid suspension (12.5 mg/mL) for Intravenous Infusion
Principal Investigator: Brad Haverkos
Eligibility: Ages ≥ 18; ECOG of 0-1; diagnosed CTCL or Nodal TCL
COMIRB: 25-0024
Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
PI: Manali Kamdar
Eligibility: Participants must have a histologically confirmed diagnosis of Classic Follicular Lymphoma (cFL). cFL was previously categorized as Grade 1-3A per WHO-HAEM4R, but grading of classic FL is no longer mandatory. *Please see other eligibility details
COMIRB: 24-0139
A Phase III, Multicenter, Randomized Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
PI: Manali Kamdar
Eligibility: Ages 18-80; ECOG of 0, 1, or 2; Previously untreated participants with CD20-positive LBCL
COMIRB: 23-0056
A Phase 3, Open-Label, Randomized Study of A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen-Specific T Cells (MT-601) Administered to Patients with Relapsed or Refractory Non-Hodgkin and Hodgkin Lymphoma (APOLLO)
PI: Manali Kamdar
Eligibility: Ages ≥ 18; Cytologically or histologically confirmed diagnosis of NHL, HL or CLL based on the 2022 World Health Organization (WHO) criteria for hematolymphoid neoplasm
COMIRB: 22-0939
A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and CC-99282 in Patients With B-Cell Non-Hodgkin Lymphoma
PI: Manali Kamdar
Eligibility: Ages ≥ 18; ECOG of ≤2
COMIRB: 18-1439
An Open-label, Multicenter, Phase Ib/II trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in combination with Polatuzumab Vedotin in Patients with B-cell Non-Hodgkin Lymphoma
PI: Manali Kamdar
Eligibility: Age ≤18; Histologically confirmed FL, DLBCL, or MCL. At least one prior systemic treatment regimen for DLBCL or FL participants containing an anti-CD20-directed therapy. At least two prior systemic treatment regiments for MCL participants which include 1) anti-CD20-directed therapy, 2) BTK inhibitor, and 3) anthracycline or bendamustine; ECOG of ≤2
COMIRB: 22-1252
A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants with Aggressive and Indolent B-cell Malignancies (waveLINE-006)
PI: Steven Bair
Eligibility: Ages ≥ 18; diagnosed aggressive or indolent B-cell malignancies; ECOG of ≤2
COMIRB: 19-3011
A Phase 2, Open-label, Single Arm, Multicohort, Multicenter Trial to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
PI: Manali Kamdar
Eligibility: Ages ≥ 18; Relapsed or refractory follicular lymphoma (FL) (Grade 1, 2 or 3a) or marginal zone lymphoma (MZL) histologically confirmed within 6 months of screening, as assessed by local pathology; Follicular lymphoma patients: Received at least one prior line of systemic therapy; Marginal zone lymphoma patients: Received two or more prior lines of systemic therapy; ECOG of 0 or 1
COMIRB: 21-2578
Phase 1/1b Study of Bispecific CD19 and CD22 Chimeric Antigen Receptor Co-Expressing T Cells (CD19x22 CAR T) in Adolescent and Adult Patients with Relapsed and/or Refractory B-Non-Hodgkin's Lymphoma (B-NHL)
PI: Manali Kamdar
Eligibility: Ages ≥ 16; Relapsed or refractory aggressive B-cell NHL; ECOG of 0 or 1
Request an Appointment
If you would like to schedule an appointment, please give us a call.
Our intake coordinator will help you navigate the process of becoming a new patient including helping you obtain the necessary referrals, get the necessary medical records transferred, and coordinate care with your existing physicians. We are available to answer your questions about our clinic, your treatment, and participation in ongoing clinical trials.